A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in Type-2 Diabetes Mellitus Subjects Not Optimally Controlled (A1C less than or equal to 7.0%) on Fixed Doses of Insulin Therapy.
Phase of Trial: Phase I
Latest Information Update: 28 May 2013
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 01 Jun 2012 Results published in the Diabetes, Obesity and Metabolism.
- 23 Aug 2010 New trial record